Monitor upcoming quarterly results for confirmation of the 17-20% revenue growth guidance and progress toward positive GAAP net income. The high specification rate in clinical trials (>70%) provides a long-term revenue visibility moat, but near-term execution on multi-product penetration and margin expansion will determine stock trajectory.
Price Chart
Executive Summary
BioLife Solutions filed an 8-K furnishing an investor presentation for the Jefferies Global Healthcare Conference. The presentation highlights FY2025 revenue of $96M (29% organic growth), 26% adjusted EBITDA margin, and provides 17-20% revenue growth guidance for FY2026, with expectations of positive GAAP net income for the full year. The filing is a routine investor relations update with no new material financial disclosures beyond previously reported figures.
Key Facts
- FY2025 revenue of $96M with 29% organic growth
- FY2025 adjusted EBITDA margin of 26%
- FY2025 gross margin of 65%
- 17-20% revenue growth guidance for FY2026
- Expects positive GAAP net income for FY2026
- Q1 2026 revenue of $27.5M
- Products specified in >70% of cell-based therapy clinical trials and ~90% of commercially relevant FDA-approved cell-based therapies
- Net cash balance of $114M as of FY2025
- Investor presentation furnished as EX-99.1 for use at Jefferies Global Healthcare Conference
Financial Impact
FY2025 revenue $96M, 29% organic growth; FY2026 revenue growth guidance 17-20%; Q1 2026 revenue $27.5M
Risk Factors
- Cell therapy market growth may not materialize as forecast
- Customer concentration risk with large biopharma partners
- Execution risk on multi-product penetration and margin expansion
- Potential competitive displacement in biopreservation media
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-040048 |
| Document: blfs-20260603.htm | 0001628280-26-040048 |
| Document: 0001628280-26-040048-index-headers.html | 0001628280-26-040048 |
| Document: 0001628280-26-040048-index.html | 0001628280-26-040048 |
| Document: 0001628280-26-040048.txt | 0001628280-26-040048 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 4, 2026 28d ago | DEFM14A | $35.38 $36.39 | ▲ +2.85% | ▲ +3.97% | $37.30 (+5.43%) |
Jun 3, 2026 17w ago | 8-K | $27.25 $26.66 | ▼ −2.17% | ▲ +1.65% | $37.30 (+36.88%) |
Apr 28, 2026 22w ago | 10-K/A | $19.99 $21.75 | ▲ +8.80% | ▲ +5.69% | $37.30 (+86.59%) |
Mar 3, 2026 30w ago | Insider Cluster | $20.17 $18.67 | ▲ +7.44% | ▲ +6.96% | $37.30 (−84.93%) |
Mar 3, 2026 30w ago | Insider Cluster | $20.17 $18.67 | ▼ −7.44% | ▼ −6.96% | $37.30 (+84.93%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access